[[PAGE:1]]

RECOMMENDATIONS

For EGFR-positive metastatic NSCLC, the authorised product may be considered in first-line per current EU practice when aligned with the approved label.

[[PAGE:2]]

BIOMARKER TESTING

Validated EGFR mutation testing should be completed before treatment selection. Later-line mutation-specific decisions require label alignment.

[[PAGE:3]]

FIRST-LINE THERAPY

Separate labeled first-line metastatic use from adjuvant or post-resection settings. Do not imply non-labeled lines are approved.